Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
Dual TTK/PLK1 inhibition represents a novel approach for the treatment of human cancer, including TNBC patients, with a potential for potent anticancer activity and a favorable therapeutic index. Moreover, combination approaches may provide an avenue to expand responsive patient populations.
Authors
- Nicole Forster (ORCID: https://orcid.org/0009-0003-7752-3010)
- Adrian Brüngger
- Anna C. Groner
- Luc Bury
- Elisa Zanini
- Nicole Willemsen‐Seegers
- Rogier C. Buijsman (ORCID: https://orcid.org/0000-0002-2757-2899)
- Mila Roceri
- Laurenz Kellenberger
- Karine Litherland (ORCID: https://orcid.org/0009-0000-8243-0482)
- Guido J.R. Zaman (ORCID: https://orcid.org/0000-0002-2477-8314)
- Diep Vu‐Pham
- Heidi A. Lane (ORCID: https://orcid.org/0000-0003-4721-0411)
- Karin Burger (ORCID: https://orcid.org/0000-0001-8812-8065)
- Felix Bachmann (ORCID: https://orcid.org/0009-0006-2822-8252)
- Martin Stieger
- Helma W. E. van Riel
- Paul M.J. McSheehy
- Jos de Man
Institutions
- Basilea Pharmaceutica (Switzerland) (CH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-09
- DOI
- https://doi.org/10.3389/fonc.2024.1447807
- Citations
- 6
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 1.96
Funders
- Basilea Pharmaceutica